Barriers to care in neovascular age-related macular degeneration: Current understanding, developments, and future directions
A Choi, BS Nawash, K Du, J Ong, J Chhablani - Survey of Ophthalmology, 2024 - Elsevier
Neovascular age-related macular degeneration is the advanced and irreversible stage of
age-related macular degeneration, the leading cause of severe vision loss in older adults …
age-related macular degeneration, the leading cause of severe vision loss in older adults …
Delayed follow-up of medical retina patients due to COVID-19: impact on disease activity and visual acuity
LG Stone, ME Grinton, JS Talks - Graefe's Archive for Clinical and …, 2021 - Springer
Purpose The coronavirus pandemic has prompted unprecedented delays to treatment with
anti-VEGF intravitreal injections due to the need to reduce hospital attendances and …
anti-VEGF intravitreal injections due to the need to reduce hospital attendances and …
Real-world evidence in the use of Bevacizumab in age-related macular degeneration (ArMD): a scoping review
A Gomez-Lumbreras, P Ghule, R Panchal… - International …, 2023 - Springer
Purpose Pharmacological treatments for age-related macular degeneration (ArMD) include
anti-vascular endothelial growth factor therapies. Bevacizumab is used off-label, as it has no …
anti-vascular endothelial growth factor therapies. Bevacizumab is used off-label, as it has no …
Loss to Follow-up in Patients with Neovascular Age-Related Macular Degeneration Treated with Anti–VEGF Therapy in the United States in the IRIS® Registry
RN Khurana, C Li, F Lum - Ophthalmology, 2023 - Elsevier
Purpose To determine the incidence of being lost to follow-up (LTFU) and nonpersistence in
patients with neovascular age-related macular degeneration (AMD) treated with anti–VEGF …
patients with neovascular age-related macular degeneration (AMD) treated with anti–VEGF …
[PDF][PDF] Wet age-related macular degeneration: treatment advances to reduce the injection burden
CR Baumal - Am J Manag Care, 2020 - ajmc.s3.amazonaws.com
Wet Age-Related Macular Degeneration: Treatment Advances to Reduce the Injection Burden
Page 1 THE AMERICAN JOURNAL OF MANAGED CARE® Supplement VOL. 26, NO. 5 S103 …
Page 1 THE AMERICAN JOURNAL OF MANAGED CARE® Supplement VOL. 26, NO. 5 S103 …
Short-term effects of COVID-19-related deferral of intravitreal injection visits
N Ashkenazy, L Goduni, WE Smiddy - Clinical Ophthalmology, 2021 - Taylor & Francis
Purpose To determine secondary effects of the mandated COVID-19 pandemic closure
period for elective treatment on non-elective, injection-based retina care and outcomes …
period for elective treatment on non-elective, injection-based retina care and outcomes …
The effect of treatment discontinuation during the COVID-19 pandemic on visual acuity in exudative neovascular age-related macular degeneration: 1-year results
M Stattin, D Ahmed, A Graf, AM Haas… - Ophthalmology and …, 2021 - Springer
Introduction To evaluate the effect of a 9-week treatment deferral due to healthcare
restrictions caused by Austria's first governmental lockdown associated with the coronavirus …
restrictions caused by Austria's first governmental lockdown associated with the coronavirus …
Outcomes in patients resuming intravitreal anti–vascular endothelial growth factor therapy following treatment delay during the coronavirus-19 pandemic
Purpose: To evaluate the outcomes of delay in care secondary to the coronavirus pandemic
in patients requiring intravitreal anti–vascular endothelial growth factor therapy. Methods: A …
in patients requiring intravitreal anti–vascular endothelial growth factor therapy. Methods: A …
Treatment of neovascular age related macular degeneration during COVID-19 pandemic: The short term consequences of unintended lapses
MA Sekeroglu, H Kilinc Hekimsoy… - European Journal …, 2022 - journals.sagepub.com
Aim: To investigate the short-term effects of COVID-19 pandemic related unintended
treatment lapses on neovascular age related macular degeneration (nAMD) patients …
treatment lapses on neovascular age related macular degeneration (nAMD) patients …
Outcomes of eyes with diabetic macular edema that are lost to follow-up after anti–vascular endothelial growth factor therapy
DR Matsunaga, M Salabati, A Obeid… - American Journal of …, 2022 - Elsevier
Purpose To evaluate the effect of loss to follow-up (LTFU) on outcomes in eyes with diabetic
macular edema (DME) treated with anti–vascular endothelial growth factor (VEGF). Design …
macular edema (DME) treated with anti–vascular endothelial growth factor (VEGF). Design …